Collaborative Innovation in CDMOs: Interview Series with Pharmaceutical Technology (5-part)

This 5-part Pharmaceutical Technology interview series with Dave Miller, Ph.D., CSO of AustinPx, explores how the role of CDMOs is evolving from transactional service providers to true co-developers. Across the series, Dave shares insights on early engagement strategies, protecting and leveraging intellectual property, and applying advanced formulation tools like KinetiSol to solve complex drug delivery challenges. Each installment highlights a different facet of “collaborative innovation,” from phase-appropriate formulation design to navigating global regulatory pathways. Drawing on AustinPx’s unique perspective as a former sponsor company, the discussions emphasize how a high-touch, high-science approach can improve asset value and accelerate development. Together, the series offers a blueprint for building CDMO partnerships that deliver lasting commercial and clinical success.